Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial (vol 374, pg 1503, 2009)

被引：0
|
作者：
Comi, G.
Martinelli, V
Rodegher, M.
机构：
来源：
LANCET | 2010年 / 375卷 / 9724期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1436 / 1436
页数：1
相关论文
共 50 条
  • [41] Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
    Kapoor, Raju
    Furby, Julian
    Hayton, Thomas
    Smith, Kenneth J.
    Altmann, Daniel R.
    Brenner, Robert
    Chataway, Jeremy
    Hughes, Richard A. C.
    Miller, David H.
    LANCET NEUROLOGY, 2010, 9 (07): : 681 - 688
  • [42] Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
    Lublin, Fred
    Miller, David H.
    Freedman, Mark S.
    Cree, Bruce A. C.
    Wolinsky, Jerry S.
    Weiner, Howard
    Lubetzki, Catherine
    Hartung, Hans-Peter
    Montalban, Xavier
    Uitdehaag, Bernard M. J.
    Merschhemke, Martin
    Li, Bingbing
    Putzki, Norman
    Liu, Fonda C.
    Haering, Dieter A.
    Kappos, Ludwig
    LANCET, 2016, 387 (10023): : 1075 - 1084
  • [43] Rituximab in patients with primary progressive multiple sclerosis: demographics in a Phase II/III randomised, double-blind, placebo-controlled multicentre trial
    Hawker, K.
    Freedman, M. S.
    O'Connor, P.
    Calabresi, P.
    Antel, J. P.
    Pallitch, H.
    Simon, J.
    Hauser, S.
    Sarkar, N.
    Agarwal, S.
    Langer-Gould, A.
    Smith, C.
    MULTIPLE SCLEROSIS, 2007, 13 : S165 - S165
  • [44] Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial (vol 12, pg 339, 2013)
    Allen, C.
    LANCET NEUROLOGY, 2013, 12 (09): : 846 - 846
  • [45] Effect of Diamel in patients with metabolic syndrome: A randomized double-blind placebo-controlled study
    Cabrera-Rode, Eduardo
    Orlandi, Neraldo
    Padron, Yaneysi
    Arranz, Celeste
    Olano, Raysa
    Machado, Mayra
    Hernandez-Yero, Arturo
    Calderin, Raul
    Dominguez, Emma
    JOURNAL OF DIABETES, 2013, 5 (02) : 180 - 191
  • [46] Effect of omega-3 fatty acid treatment in multiple sclerosis (OFAMS study): results from a randomised, double-blind, placebo-controlled trial
    Torkildsen, O.
    Beiske, A.
    Hovdal, H.
    Midgard, R.
    Bjorna, I.
    Henriksen, O.
    Schepel, J.
    Eikeland, R.
    Kristensen, T.
    Kierulf, H.
    Dalane, F.
    Bru, A.
    Kleveland, G.
    Wergeland, S.
    Myhr, K.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S412 - S412
  • [47] Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis (vol 82, pg 970, 2011)
    Yoshikawa, H.
    Kiuchi, T.
    Saida, T.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2011, 82 (10): : 1180 - 1180
  • [48] A randomised, double-blind, placebo-controlled trial on the effect of Pycnogenol® on the climacteric syndrome in peri-menopausal women
    Yang, Han-Ming
    Liao, Mei-Fen
    Zhu, Shu-Yuan
    Liao, Mei-Nan
    Rohdewald, Peter
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2007, 86 (08) : 978 - 985
  • [49] Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study (vol 11, pg 420, 2012)
    Devonshire, V
    Havrdova, E.
    Radue, E. W.
    LANCET NEUROLOGY, 2012, 11 (08): : 658 - 658
  • [50] REFLEX:: a phase III trial to assess the effect of dosing frequency of interferon beta-1 a (Rebif®) in delaying conversion of patients with a clinically isolated syndrome to clinically definite multiple sclerosis
    Kappos, L.
    Freedman, M.
    De Stefano, N.
    Labauge, R.
    Comi, G.
    Stubinski, B.
    JOURNAL OF NEUROLOGY, 2007, 254 : 103 - 103
12345